Innovent Biologics Inc (1801):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Innovent Biologics Inc (1801) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11176
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Innovent Biologics Inc (Innovent Biologics) is a biopharmaceutical company that discovers, develops and manufactures monoclonal antibodies. The company offers monoclonal antibodies such as IBI301, IBI302 and IBI303, among others. Its products are used for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, crohn’s disease, and other autoimmune diseases. Innovent Biologics development platform provides pilot process development and preclinical and clinical research stage that shortens the development cycle of new drugs. The company operates in fields of oncology, autoimmune disease and ophthalmology with application to different indications. It markets its products across China. Innovent Biologics is headquartered in Suzhou, China.

Innovent Biologics Inc (1801) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innovent Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Innovent Biologics Raises USD150 Million in Series E Venture Financing 11
Innovent Biologics May Raise Funds through Venture Financing 13
Innovent Biologics Raises USD260 Million in Series D Financing 14
Innovent Biologics Raises USD100 Million in Series C Venture Financing 16
Innovent Biologics Raises US$25 Million In Series B Financing 17
Innovent Biologics Raises US$5 Million In Series A Venture Financing Round 18
Partnerships 19
Hanmi Pharma Enters into Co-Development Agreement with Innovent Biologics 19
EpimAb Biotherapeutics Enters into Co-Development Agreement with Innovent Biologics 20
Eli Lilly Expands Agreement with Innovent Biologics 21
Adimab Expands Agreement with Innovent Biologics 22
Aragen Bioscience Enters Into Co-Development Agreement With Innovent Biologics For Biotherapeutic Products 23
Licensing Agreements 24
Harbour BioMed Enters into Licensing Agreement with Innovent Biologics 24
Innovent Biologics Enters into Licensing Agreement with Chinese Academy and Shanghai Institute of Organic 25
Equity Offering 26
Innovent Biologics Prices IPO of Shares for USD422 Million 26
Innovent Biologics Inc – Key Competitors 28
Innovent Biologics Inc – Key Employees 29
Innovent Biologics Inc – Locations And Subsidiaries 30
Head Office 30
Recent Developments 31
Product News 31
07/25/2018: Innovent receives IND approval to initiate clinical trials in china with its aanti-RANKL Antibody IBI307 31
07/25/2018: Innovent receives IND approval to initiate clinical trials in china with its anti-OX40 Agonistic Antibody IBI101 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innovent Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innovent Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Innovent Biologics Raises USD150 Million in Series E Venture Financing 11
Innovent Biologics May Raise Funds through Venture Financing 13
Innovent Biologics Raises USD260 Million in Series D Financing 14
Innovent Biologics Raises USD100 Million in Series C Venture Financing 16
Innovent Biologics Raises US$25 Million In Series B Financing 17
Innovent Biologics Raises US$5 Million In Series A Venture Financing Round 18
Hanmi Pharma Enters into Co-Development Agreement with Innovent Biologics 19
EpimAb Biotherapeutics Enters into Co-Development Agreement with Innovent Biologics 20
Eli Lilly Expands Agreement with Innovent Biologics 21
Adimab Expands Agreement with Innovent Biologics 22
Aragen Bioscience Enters Into Co-Development Agreement With Innovent Biologics For Biotherapeutic Products 23
Harbour BioMed Enters into Licensing Agreement with Innovent Biologics 24
Innovent Biologics Enters into Licensing Agreement with Chinese Academy and Shanghai Institute of Organic 25
Innovent Biologics Prices IPO of Shares for USD422 Million 26
Innovent Biologics Inc, Key Competitors 28
Innovent Biologics Inc, Key Employees 29

List of Figures
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Innovent Biologics Inc (1801):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PaR Systems LLC:企業の戦略的SWOT分析
    PaR Systems LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Oil States International, Inc.:企業の戦略・SWOT・財務情報
    Oil States International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Oil States International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Eiffage SA (FGR):電力:M&Aディール及び事業提携情報
    Summary Eiffage SA (Eiffage) is a construction and concession company. It operates in businesses of energy and infrastructure construction, real estate development, road construction, civil engineering, concessions, and public-private partnerships. The company’s activities include construction, reno …
  • Avista Corporation (AVA):電力:M&Aディール及び事業提携情報
    Summary Avista Corporation (Avista) is an electric and natural gas utility. The company produces, transmits, and distributes electricity; and supplies natural gas on retail and wholesale basis. It sources electricity from its facilities and contracted hydroelectric, thermal and wind generation facil …
  • Pharmaceutical Product Development LLC-製薬・医療分野:企業M&A・提携分析
    Summary Pharmaceutical Product Development LLC (PPD) is a contract research organization (CRO), which offers drug discovery, development and lifecycle management services. The company’s service portfolio encompasses early development clinical trial services, drug research and development, regulatory …
  • Internap Corp (INAP):企業の財務・戦略的SWOT分析
    Summary Internap Corp (Internap), formerly Internap Network Services Corp is an information technology company that provides internet infrastructure solutions. The company offers bare-metal cloud, hosting and colocation services. Internap provides collocation services such as power, interconnection, …
  • Flexible Solutions International Inc (FSI):企業の財務・戦略的SWOT分析
    Flexible Solutions International Inc (FSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Kemwell Biopharma Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Kemwell Biopharma Pvt Ltd (Kemwell) formerly Kemwell Pvt Ltd a subsidiary of Recipharm AB is a healthcare solutions provider that offers product development and manufacturing solutions. The organization provides contract pharmaceutical development and manufacturing organization and concentra …
  • Salem Media Group, Inc.:企業の戦略・SWOT・財務分析
    Salem Media Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Salem Media Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Altern Energy Ltd (ALTN):企業の財務・戦略的SWOT分析
    Altern Energy Ltd (ALTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Inretail Peru Corp.:企業の戦略的SWOT分析
    Inretail Peru Corp. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Linamar Corporation (LNR):企業の財務・戦略的SWOT分析
    Linamar Corporation (LNR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Oracle Financial Services Software Limited (OFSS):企業の財務・戦略的SWOT分析
    Oracle Financial Services Software Limited (OFSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Callon Petroleum Co (CPE):石油・ガス:M&Aディール及び事業提携情報
    Summary Callon Petroleum Co (CPC) is an oil and gas company that offers building reserves and production of onshore and offshore oil and natural gas. The company carries out acquisition, development, exploration, and exploitation of unconventional onshore, oil, and natural gas reserves. It operates …
  • Guangdong Carpoly Chemical Group Co Ltd:企業の戦略的SWOT分析
    Guangdong Carpoly Chemical Group Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • 4SC AG (VSC):製薬・医療:M&Aディール及び事業提携情報
    Summary 4SC AG (4SC) is a biopharmaceutical company that discovers and develops small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s product focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its product pipeline comprises therapeutic programs at v …
  • Bechtle AG (BC8):企業の財務・戦略的SWOT分析
    Summary Bechtle AG (Bechtle) is an information technology (IT) products retailer. The company’s retails products such as hardware devices and software. It provides notebooks, tablets, smartphones, mobile phones, wearables, power banks, spare parts, accessories, monitors, public display, projectors, …
  • Bioxyne Ltd (BXN):企業の財務・戦略的SWOT分析
    Bioxyne Ltd (BXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • 3-D Matrix Ltd (7777):医療機器:M&Aディール及び事業提携情報
    Summary 3-D Matrix Ltd (3-D Matrix) is a regenerative medicine company that focuses at commercializing its self-assembling peptide technology. It develops medical products by applying this technology under a license granted by Massachusetts Institute of Technology (MIT). The technology finds applica …
  • Paladin Energy Ltd.:企業の戦略的SWOT分析
    Paladin Energy Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆